J. Millichap, WINSTON R. Ortiz
Feb 1, 1967
Citations
0
Influential Citations
9
Citations
Quality indicators
Journal
Neurology
Abstract
ALBUTOIN ( Co-ordm ) , 3-allyl-5-isobutyl-2-thiohydantoin, was synthesized by A. Berger,l and its anticonvulsant properties in laboratory animals were described by Gesler and his associates.2 Unlike diphenylhydantoin (Dilantinm) , which is effective only against the tonic component of the maximal seizure induced by electroshock,3 Co-ord@ prevents clonic as well as tonic experimental seizure patterns and has greater potency against pentylenetetrazol (Metrazolm) than electroshock seizures. Davis and Schwade4 evaluated Co-ord@ in 23 patients with seizures refractory to other anticonvulsants. Twenty-one had grand ma1 combined with psychomotor or petit ma1 epilepsies, or both, 16 had psychomotor attacks, and 11 had petit ma1 alone. The patients were treated for periods varying from three weeks to eleven months, and the dosage ranged from 0.15 to 1.2 gm. per day, with an average of 0.4 gm. daily. The ages of the patients were from 10 to 55 years. Co-ordm was given in addition to previous medications or it was substituted for one of the drugs previously used. Twelve of the 23 patients showed improvement and 11 were unchanged or their attacks occurred more frequently. The results were expressed as a group and not in relation to each seizure pattern treated. A few patients complained of dizziness or drowsiness and abdominal discomfort, and one reported a skin rash which cleared on withdrawal of the drug. The authors considered that Co-ord@